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Summary
This is the second report of the United Kingdom Primary Immunodeficiency
(UKPID) registry. The registry will be a decade old in 2018 and, as of August
2017, had recruited 4758 patients encompassing 97% of immunology centres
within the United Kingdom. This represents a doubling of recruitment into
the registry since we reported on 2229 patients included in our first report of
2013. Minimum PID prevalence in the United Kingdom is currently 590/
100 000 and an average incidence of PID between 1980 and 2000 of 76 cases
per 100 000 UK live births. Data are presented on the frequency of diseases
recorded, disease prevalence, diagnostic delay and treatment modality,
including haematopoietic stem cell transplantation (HSCT) and gene therapy.
The registry provides valuable information to clinicians, researchers, service
commissioners and industry alike on PID within the United Kingdom, which
may not otherwise be available without the existence of a well-established
registry.
Keywords: autoimmunity, autoinflammatory disease, human, immunodefi-
ciency diseases, transplantation
Introduction
Primary immunodeficiencies (PID) are rare diseases, with
a reported prevalence of between 1 : 16 000 and 1 : 50 000
[1]. The small numbers of patients cared for by individual
centres provides challenges to effective diagnosis, clinical
care and research. National and international registries
have sought to overcome these barriers by encouraging col-
laboration and providing valuable data sets to clinicians,
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researchers, pharmaceutical companies and health policy-
makers. The United Kingdom Primary Immunodeficiency
(UKPID) registry has provided a unique repository of lon-
gitudinal UK data. It was established in 2008 and the first
report was published in 2013, covering the first 4 years of
activity (2008–12) [2]. The registry has now expanded to
4758 patients from the 2229 patients in our first report,
highlighting the success and efforts of the registry team and
local collaborators. While much data overlap with the
European Society for Immunodeficiencies (ESID) registry,
establishing a standalone UKPID registry allows the addi-
tion of variables that are of importance to UK PID clini-
cians and researchers that may not otherwise be available
from the ESID registry.
Improved recognition of PID and advances in molecular
diagnostics have led to a significant increase in the num-
bers of individual PIDs being recognized, with nearly 300
genes identified [3]. It is increasingly recognized that these
PIDs not only present with increased susceptibility to
infections, but also immune dysregulation, autoimmunity
and an increased susceptibility to malignancy. In addition,
an ever-expanding range of treatment options are now
available, resulting in improved patient outcomes. Reduced
morbidity and mortality following haematopoietic stem
cell transplantation (HSCT) means that clinicians are more
willing to offer this therapy to a wider range of patients,
including adults with PID, and to a greater range of PIDs
in a bid for complete cure. Furthermore, new strategies
such as gene therapy and newborn screening for severe
combined immunodeficiency (SCID), molecular therapy
(e.g. Janus kinase inhibitors) and monoclonal antibody
therapy are now viable options to include within the UK
health-care system. Data from national registries provide
vital information for clinicians and health policy planners
in evaluating the merits of the potential introduction of
such strategies.
Methods
The development, ongoing management and technical
database structure of the registry was described in our first
report [2,4–6]. Multicentre Research Ethics (MREC)
approval was obtained in 2004 for the ESID online data-
base (MREC number: 04/MRE07/68). Approvals have been
amended to reflect the establishment of a UK-based
database.
A retrospective analysis of the registry data was per-
formed. Minimum prevalence and incidence, as well as live
birth data, were calculated using UK population data
sourced from the Office for National Statistics estimates
[7–10]. Annual incidence rates have been calculated per
100 000 UK population. Data relating to geographical,
gender and sex distribution in addition to age of onset
and diagnostic delay were analysed using parametric and
non-parametric analysis as appropriate. Where data were
available for only a subset of the patients the denominator
is stated within the text. The UKPID registry also collects
data on patients with secondary antibody deficiency. These
patients have been excluded from data pertaining to preva-
lence and incidence of PID as well as International Union
of Immunological Sciences (IUIS) category breakdown.
Their data have been included to demonstrate their
diagnostic delay and immunoglobulin data due to the
significant contribution this patient group make to the UK
clinical immunology workload and as a comparator cohort
for immunoglobulin-treated patients with infection.
Data quality continues to be heavily reliant upon quali-
fied users inputting data. Contributing centres are well
established within the primary immunodeficiency field.
Users must be approved by their head of department and
are trained in the documentation of medical data. There is
additional ongoing data monitoring by a registry co-
ordinator and a nominated person in each centre. The
database itself has further features to assure data quality,
e.g. mandatory fields and logic rules. New entries are
reviewed by the registry co-ordinator to ensure that no
replication has occurred. In addition, the registry is inter-
rogated on a regular basis to detect and correct any further
duplicated entries.
Results
There are currently 38 recognized centres in the United
Kingdom providing specialist immunology services, 37 of
which (97%) are enrolling patients actively into the UKPID
database, compared to 71% in 2012 (Fig. 1). As of August
2017, 4758 patients have been entered into the registry.
Recruitment has increased significantly since our 2013
report, which included data on 2229 patients (Fig. 2); 4258
patients were alive and being followed-up (895%).
Excluding those patients with secondary antibody
deficiency (n 5 369), this equates to a minimum 2017 UK
PID prevalence of 590/100 000. Three hundred (63%)
patients have died since being entered into the database
from the ESID database inception in 2004 and this UKPID
registry in 2008. Antibody disorders make up the largest
group of patients within the registry, with a minimum UK
prevalence of 392/100 000 (n 5 2589, 60%). Prevalence
data for the nine IUIS classification categories [3] are
shown in Table 1. There were 2399 females and 2359 males
registered. Eight hundred and seven (170%) patients were
aged 16 years or younger at the time of the latest data entry
and collection.
Consanguinity was reported in 118 of 4097 cases (29%),
equal to the proportion in our previous report (29%).
Nine hundred and sixty-eight of 3971 available cases were
identified as familial cases (244%), as per our previous
report of 240%. One thousand and thirty-five (218%)
patients had a proven genetic defect underlying their PID.
Of patients with agammaglobulinaemia, 57% (177) had a
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defect in BTK and one patient had a defect in the Immuno-
globulin Heavy Constant Mu (IGHM) gene; 755%
(n 5 142) patients with severe combined immunodefi-
ciency (SCID) had a proven genetic defect, with common
gamma chain being the most common, accounting for
324% (n 5 46) of cases. A full breakdown of the genetic
defects found in the SCID registry patients is shown in
Table 2. Of patients with chronic granulomatous disease
(CGD), 666% (n 5 96) had a proven genetic defect, with
mutations in CYBB gene encoding the gp91-phox protein
accounting for the majority of cases (688%, n 5 66).
Eighteen (27%) of the 678 for whom data were available
had their genetic defect diagnosed using whole exome
sequencing.
Antibody disorders continue to make up the largest
group of all registered patients, accounting for 2821
(597%) of a total of 4727 registry patients for whom diag-
nosis was recorded. The most frequently reported PID is
common variable immunodeficiency (CVID), accounting
for 1404 patients (297%). The second most frequent
diagnosis was hereditary angioedema (HAE) (n 5 514,
109%). Secondary hypogammaglobulinaemia (n 5 409,
87%), unclassified antibody deficiencies (n 5 310, 66%),
agammaglobulinaemia (n 5 209, 44%), unclassified
immunodeficiencies (n 5 191, 40%), SCID (n 5 188,
40%) and specific antibody deficiency (n 5 165, 35%)
were the next most frequent reported diagnoses. The mini-
mum UK prevalence for CVID is 193/100 000 population,
HAE 073/100 000, secondary hypogammaglobulinaemia
056/100 000, unclassified antibody deficiency 043/
100 000, agammaglobulinaemia 030/100 000 and SCID
026/100 000. A full list of prevalence rates for all diseases
recorded within the registry can be found in Supporting
information, Table S1.
The median annual prevalence of PID from 2010 to 2015
was 038 new cases per 100 000 UK population (one per
270 270), peaking at 044 new cases per 100 000 UK popula-
tion in 2012 (one per 227 518). The incidence per 100 000
UK live births is shown in Fig. 3. There is a clear rise in inci-
dence per 100 000 live UK births from the mid-1980s. This
is likely to be due to an increased recognition of PID, result-
ing in more patients being entered into the registry enabling
a truer reflection of incidence. In addition, with modern
management, many patients are expected to live into adult-
hood, thereby increasing the number of cases of inherited
PID in addition to any de-novo genetic mutations. The appa-
rent drop in incidence from 2000, seen in Fig. 3, is a result
of cases born in this time-period not yet diagnosed with PID
(e.g. CVID). From 1980 to 2000 the minimum median inci-
dence of PID was 760 cases per 100 000 UK live births or
one per 13 157 births.
Diagnostic delay can affect outcome negatively in PID.
Prompt diagnosis improves outcomes following HSCT for
SCID [11–13] and is recognized as an important prognos-
tic indicator in antibody deficiencies [14–16]. The current
median diagnostic delay for SCID was 60 days [interquar-
tile range (IQR) 5 0–121]. The current median diagnostic
delay in CVID was 4 years (IQR 5 1–10). Spearman’s
Fig. 1. Geographical distribution of patients enrolled in the United
Kingdom Primary Immune Deficiency (UKPID) Registry by city or
town of documenting centre. The diameter of the circle is directly
proportional to the number of patients enrolled in each centre.
Fig. 2. Recruitment of total patient numbers into the United
Kingdom Primary Immunodeficiency Registry.
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correlation demonstrates a statistically significant but weak
correlation for a decreasing diagnostic delay over time for
CVID (rs 5 –00719, P 5 00213). For agammaglobulinae-
mia the median delay is 1 year (IQR 5 0–2). For the 3912
patients for whom data are available, the main presenting
symptom is infection-related, accounting for 768% of
patients, followed by immune dysregulation with 81%. Pre-
senting symptom and diagnostic delay by diagnosis and
IUIS category are shown in Table 3.
A total of 2836 patients are recorded to have received
immunoglobulin replacement therapy (596% of the total
4758 registry patients); 1391 (49%) received this by
intravenous route and 1440 (51%) by subcutaneous route;
and 1669 (589%) received their infusion at home. The
median dose of immunoglobulin was 514 mg/kg/month
(IQR 5 424–645), with a median interval of 3 weeks.
A total of 679 patients were recorded as having received
an HSCT since 1973, with the majority (872%) trans-
planted after 2000 (Fig. 4). Three hundred and ten (457%)
received their HSCT from donor blood marrow, 200
(295%) from peripheral blood stem cells, 59 (87%) from
cord blood stem cells and in 110 (162%) the donor was
not recorded. Two hundred and ninety-four (433%) were
matched unrelated donor (MUD), 167 (246%) matched
sibling donor (MSD), 77 (113%) haploidentical, 73
(108%) mismatched unrelated donor (MMUD), two
(03%) autologous and the source was unrecorded in 66
(97%). Autologous HSCT is not a standard of care in PID;
there are no further data on these two cases recorded in
this registry. The overall survival rate for HSCT in this
registry is 838% with a mortality of 77% (85% are either
discharged or lost to follow-up). Since 2000, 26 patients
have undergone gene therapy. The survival for gene therapy
patients in the registry is currently 100%.
Discussion
The UKPID registry celebrates its 10th birthday in 2018.
During this decade almost all immunology centres in the
United Kingdom have contributed actively to the database,
and the number of recruited patients continues to grow
each year. London and Newcastle (supraregional centres for
transplantation of paediatric PID) continue to provide a
large contribution to the database (accounting for 250%
and 126% of the total registry, respectively). The wide geo-
graphical spread of actively recruiting centres should
ensure that the registry reflects accurately the pattern of
health-care service access and delivery throughout the
United Kingdom.
The UKPID registry allows easy-to-access and reliable
data sets for clinicians and researchers. This enables
assessment of patient outcomes to be performed in a timely
and effective manner, such as that seen in the recent work
from Stubbs et al. [17], suggesting that patients with
agammaglobulinaemia in the United Kingdom suffer from
deteriorating pulmonary health despite current therapies.
Table 1. Frequency table for International Union of Immunological
Sciences (IUIS) classification and minimum disease prevalence
IUIS classification
n (alive
patients)
UK prevalence/
100 000
Autoinflammatory disorders 25 004
Combined immunodeficiencies 329 050
Complement deficiencies 559 085
Defects in innate immunity 39 006
Diseases of immune dysregulation 94 014
Other well-defined PIDs 325 049
Phagocytic disorders 177 027
Predominantly antibody disorders 2589 392
Unclassified immunodeficiencies 160 024
Estimated minimum prevalence data for primary immunodefi-
ciency (PID) in the United Kingdom is based on a national popula-
tion of 66 029 990 (source: Office for National Statistics).
Table 2. Genetic defects in SCID registry patients
Genetic defect
Number
of
cases
Proportion
(%)
Common gamma chain (X-linked) 46 3239
ADA 38 2676
IL-7Ra 14 986
JAK3 11 775
RAG1 15 1056
Artemis 10 704
RAG2 3 211
IL-21R 3 211
CD3e 1 070
LIG4 1 070
ADA 5 adenosine deaminase; IL 5 interleukin; JAK3 5 Janus
kinase 3; RAG 5 recombination activating; LIG4 5 DNA ligase 4;
SCID 5 severe combined immunodeficiency.
Fig. 3. UK incidence of registered primary immunodeficiency (PID)
per 100 000 live births.
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Compiling such a body of work without the aid of the
UKPID registry would result in considerable additional
workload and time to the research process.
Since our first report, we estimated the number of
patients with PID in the United Kingdom to be between
4000 and 5000. Our latest count of 4258 verified live
patients is extremely encouraging. The minimum preva-
lence of PID in the United Kingdom with these latest data
stands at 590/100 000 population. This is similar to the
reported incidence in France of 606 per 100 000 and larger
than Switzerland (416 per 100 000) and Germany (211
per 100 000) [1]. These disparities are likely to be due to
differences in reporting, as individual countries continue to
develop their own reporting strategies. With the coverage
of the UKPID registry (97% of immunology centres), we
feel this minimum incidence is an accurate reflection of the
burden of PID within the general population. It is possible
that this is still an underestimate, with some patients not
recruited to the registry and some patients being treated at
hospitals not designated as immunology centres, but these
numbers are likely to be small. However, a recent epidemi-
ological field survey from Mahlaoui et al. [18] suggests that
the true minimum prevalence of PID in France is actually
11 per 100 000 population, and may therefore mean that
these numbers still underestimate significantly the true
burden of PID within the population.
The expansion in registry patients also enables us to cal-
culate a reliable estimate of PID incidence per UK annual
live births. The data showed a median PID incidence from
1980 to 2000 of one in 13 157 births. This number is still
likely to be an underestimate of the true value, with a
Table 3. Diagnostic delay and main presenting symptom for the most common primary immunodeficiencies (PIDs) and International Union of
Immunological Societies (IUIS) category in years (median, 25th and 75th quartiles)
Min
25th
quartile Median
75th
quartile Max
Immune
dysregulation Infections Malignancy Syndromal Other
PID
CVID 0 1 4 10 69 51% 937% 01% 01% 10%
Hereditary angioedema 0 0 2 10 55 00% 03% 00% 20% 977%
Secondary hypogammaglobulinaemia 0 0 1 3 64 19% 967% 08% 00% 06%
Agammaglobulinaemia 0 0 1 2 44 00% 982% 00% 06% 12%
Unclassified antibody deficiency 0 1 2 5 61 30% 937% 03% 03% 26%
Age (years)
< 18 0 0 0 1 14 192% 657% 00% 87% 64%
Between 18 and 65 0 1 3 8 48 12% 896% 04% 04% 84%
> 65 0 1 3 10 69 70% 762% 03% 16% 149%
IUIS category
Autoinflammatory disorders 0 25 6 105 33 818% 00% 00% 91% 91%
Combined immunodeficiencies 0 0 0 1 47 176% 779% 00% 15% 31%
Complement deficiencies 0 0 1 8 55 00% 106% 00% 19% 874%
Defects in innate immunity 0 1 2 6 61 48% 881% 00% 48% 24%
Diseases of immune dysregulation 0 0 1 4 43 670% 262% 00% 49% 19%
Other well-defined PIDs 0 0 1 35 66 199% 507% 00% 272% 22%
Phagocytic disorders 0 0 1 3 37 145% 836% 00% 12% 06%
Predominantly antibody disorders 0 1 3 8 69 35% 943% 04% 01% 16%
Unclassified immunodeficiencies 0 0 2 9 66 148% 800% 07% 22% 22%
Presenting symptom
Immune dysregulation 0 0 1 6 43
Infections 0 1 2 6 67
Malignancy 0 3 4 425 5
Syndromal 0 0 1 8 55
Other 0 0 0 225 11
PID 5 primary immunodeficiency; CVID 5 common variable immunodeficiency; IUIS 5 International Union of Immunological Societies.
Fig. 4. Number of primary immunodeficiency (PID) patients
undergoing haematopoietic stem cell transplantation (HSCT) or
gene therapy.
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significant proportion of patients in this period dying
either before their PID is recognized or before the estab-
lishment of the UKPID registry. With the registry now
firmly established, we hope to increase the accuracy of
these data for future reports. The proportion of under
16-year-olds in the database is currently 170%, similar to
the under 16-year-old proportion of the general UK popu-
lation at 188% [7].
Antibody deficiencies continue to account for the largest
group of PID cases within the registry (60%), has remained
stable since our first report and is in keeping with other
registries [1].
Clinicians strive continually to diagnose patients earlier
to improve patient outcomes. Nearly a quarter of patients
presented with symptoms other than recurrent infections.
Non-infectious presentations such as autoimmune cyto-
paenias, inflammatory bowel disease and malignancy are
being recognized increasingly as possible presentations of
PID [19–22]. The median diagnostic delay for patients who
presented with malignancy is 4 years, the highest amongst
the presenting symptoms recorded by our registry.
Increased awareness of these facts as demonstrated by these
data and those of others should hopefully result in reduc-
tions in diagnostic delay for future patients.
Increased awareness of the genetic basis of PID and thus
the importance of screening newborn siblings of affected
patients will help to reduce delays. Newborn screening for
SCID by measuring T cell receptor excision circles (TRECs)
on the newborn blood spot is due to start in the United
Kingdom in 2018 under a pilot programme, which may
offer significant improvements in event-free survival for
SCID patients in the United Kingdom. Diagnostic delay in
the diagnosis of agammaglobulinaemia remains consistent
at 1 year. Newborn screening for congenital B cell deficien-
cies is possible using a similar technique to SCID screening,
by measuring kappa-deleting recombination excision
circles (KRECs) on the newborn blood spot. Some coun-
tries do, indeed, combine a TREC/KREC screening
programme, but the effectiveness of a KREC screening pro-
gramme is currently unknown.
Immunoglobulin therapy remains the mainstay of treat-
ment for the vast majority of antibody deficiency syn-
dromes. The proportion of those patients receiving
intravenous immunoglobulin therapy (IVIG) has fallen
from 60% in our previous report to an equal split in the
cohort between intravenous and subcutaneous therapies
(SCIG). For the 2836 patients recorded as receiving immu-
noglobulin therapy, more than half (59%) receive their
therapy at home. These data highlight the patient prefer-
ence for therapy at home, and should continue to be
offered actively to all patients wherever possible.
Better understanding of, and access to, genetic testing
can enable faster and more accurate diagnosis of PID lead-
ing to improved outcomes [23]. Nearly a quarter of the
registry patients have a proven gene defect underlying their
PID, although the number of patients who had genetic test-
ing but no defect found is unknown in this registry’s data.
In the previous report (2014) only 20 patients had a
recorded genetic diagnosis; significant work to improve
capture of genetic diagnoses has been undertaken. Diseases
such as agammaglobulinaemia continue to show a high
proportion of cases where a genetic defect is found (85%).
However, common diseases such as CVID continue to
show a low proportion of cases for which a genetic defect is
found (178%). Next-generation sequencing looks set to
supersede conventional Sanger sequencing in the coming
years, leading to a potentially higher proportion of patients
for whom a genetic defect is known and to the discovery of
new PIDs [24].
The UKPID registry is now established firmly within the
United Kingdom and data are available for the majority of
PID patients. This data set enables a relatively accurate esti-
mate of disease burden of primary immunodeficiency
within the United Kingdom. During the next 5–10 years we
hope to continue this successful recruitment, as well as
adding the next level of registry data encompassing more
detailed diagnostic and follow-up data; e.g. infection inci-
dence, medication, vaccinations, lung function, laboratory
values and quality of life. It is also planned to include fur-
ther therapeutic data, most notably the use of biologicals
and targeted therapy, for which this registry could provide
a useful data source for surveying the use of these agents.
These extra levels of detail will further enable accurate
assessment of outcomes in PID to be performed quickly
and with relative ease than would otherwise be possible
without such a registry. As research in PID advances there
is likely to be an increasing range of interventions available
to patients. The ability to evaluate current outcomes in a
timely manner will be vital to ensuring that patients are
able to access the best possible care. We look forward to
working with researchers and clinicians in providing reli-
able, detailed data on PID within the United Kingdom to
aid research, rational resource allocation and improve-
ments in clinical care.
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